Condition: AL Amyloidosis · Sponsor: Peking University People's Hospital
This study aims to evaluate the use of teclistamab in systemic AL amyloidosis and answer whether teclistamab can improve the rate of complete hematological response. This is a single-arm, multi-center, prospective study. Participants will receive the single drug teclistamab, which the investigator deems the best choice.
This description comes directly from the study's public registry record.
Yang Dr, M.D. · +86-10-88326542 · pkuphliuyang@bjmu.edu.cn
Always discuss trial participation with your own doctor first.
| Peking University Peoples Hospital | Beijing, Beijing Municipality, China | Recruiting |
| Fuxing Hospital affiliated to Capital Medical University | Beijing, China | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT06699394